CA2733597C - Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity - Google Patents

Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity Download PDF

Info

Publication number
CA2733597C
CA2733597C CA2733597A CA2733597A CA2733597C CA 2733597 C CA2733597 C CA 2733597C CA 2733597 A CA2733597 A CA 2733597A CA 2733597 A CA2733597 A CA 2733597A CA 2733597 C CA2733597 C CA 2733597C
Authority
CA
Canada
Prior art keywords
allele
nucleic acid
haplotype
acid sequence
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2733597A
Other languages
English (en)
French (fr)
Other versions
CA2733597A1 (en
Inventor
Timothy Atchison Donlon
Bradley John Willcox
J. David Curb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KUAKINI MEDICAL CENTER
Original Assignee
KUAKINI MEDICAL CENTER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2733597(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by KUAKINI MEDICAL CENTER filed Critical KUAKINI MEDICAL CENTER
Publication of CA2733597A1 publication Critical patent/CA2733597A1/en
Application granted granted Critical
Publication of CA2733597C publication Critical patent/CA2733597C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/125—Allele specific primer extension
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2733597A 2008-08-10 2009-08-10 Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity Active CA2733597C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8772208P 2008-08-10 2008-08-10
US61/087,722 2008-08-10
PCT/US2009/053307 WO2010019519A2 (en) 2008-08-10 2009-08-10 Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity

Publications (2)

Publication Number Publication Date
CA2733597A1 CA2733597A1 (en) 2010-02-18
CA2733597C true CA2733597C (en) 2019-02-26

Family

ID=41669598

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2733597A Active CA2733597C (en) 2008-08-10 2009-08-10 Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity

Country Status (9)

Country Link
US (3) US20110212447A1 (enExample)
EP (1) EP2324127B1 (enExample)
JP (1) JP5814119B2 (enExample)
KR (2) KR20160102081A (enExample)
CN (1) CN102177255B (enExample)
AU (1) AU2009282172B2 (enExample)
CA (1) CA2733597C (enExample)
DK (1) DK2324127T3 (enExample)
WO (1) WO2010019519A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160102081A (ko) * 2008-08-10 2016-08-26 쿠아키니 메디컬 센터 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법
US8990135B2 (en) * 2010-06-15 2015-03-24 The Regents Of The University Of Michigan Personalized health risk assessment for critical care
CN103233001B (zh) * 2012-06-25 2016-11-02 西北农林科技大学 秦川牛FoxO1基因单核苷酸多态性分子标记的检测方法与应用
KR102017562B1 (ko) * 2013-03-13 2019-09-03 (주)아모레퍼시픽 미백 효능 물질의 스크리닝 방법
WO2017062751A1 (en) * 2015-10-08 2017-04-13 The Regents Of The University Of California Compounds and methods for promoting stress resistance
WO2018183353A1 (en) * 2017-03-27 2018-10-04 Cardax Pharma, Inc. Small molecule compounds to support healthy human aging
CN110915165B (zh) * 2017-05-12 2023-05-26 麻省理工学院 用于共享私有数据的计算机实现的方法和装置
WO2019156591A1 (en) * 2018-02-12 2019-08-15 Limited Liability Company "Gero" Methods and systems for prediction of frailty background
CN111235250A (zh) * 2020-03-31 2020-06-05 中国科学院昆明动物研究所 与健康老龄相关的关键通路及其外周血dna甲基化位点标志物和应用
CN115466321B (zh) * 2022-09-23 2024-03-22 南方医科大学珠江医院 FOXO3a-DRI肽段、其药物组合物及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
ATE267877T1 (de) 1993-01-07 2004-06-15 Sequenom Inc Dns - sequenzierung durch massenspektronomie
US5593826A (en) 1993-03-22 1997-01-14 Perkin-Elmer Corporation, Applied Biosystems, Inc. Enzymatic ligation of 3'amino-substituted oligonucleotides
US5747282A (en) 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5709999A (en) 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5710001A (en) 1994-08-12 1998-01-20 Myriad Genetics, Inc. 17q-linked breast and ovarian cancer susceptibility gene
US5753441A (en) 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5693473A (en) 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
EP0699754B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Method for diagnosing a predisposition for breast and ovarian cancer
US5837495A (en) 1994-10-13 1998-11-17 Applied Research Systems Ars Holding N.V. DNA encoding interleukin-1 antagonist
CA2239733C (en) 1995-12-18 2001-04-03 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US6673546B2 (en) 2000-08-11 2004-01-06 The Children's Medical Center Corporation Genetic loci indicative of propensity for longevity and methods for identifying propensity for age-related disease
US20040121407A1 (en) 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
EP1413584B1 (en) 2002-10-21 2005-03-02 AXXAM S.r.l. Photoprotein with improved bioluminescence
US7932049B2 (en) 2002-12-23 2011-04-26 University Of Massachusetts Methods of identifying longevity modulators and therapeutic methods of use thereof
DE10311769A1 (de) 2003-03-18 2004-09-30 Bayer Healthcare Ag Testmethoden zur Bestimmung der intrazellulären Konzentration zyklischer Nukleotide
US20070105109A1 (en) 2003-07-02 2007-05-10 Geesaman Bard J Sirt1 and genetic disorders
WO2005007687A1 (en) 2003-07-09 2005-01-27 Dana-Farber Cancer Institute, Inc Compositions and methods for modulating ovarian follicular initiation
JP2005168463A (ja) 2003-12-15 2005-06-30 Chisso Corp カルシウム結合型発光蛋白質の保存方法等
US20060069049A1 (en) 2003-12-29 2006-03-30 President And Fellows Of Harvard College Methods and reagents related to foxo
CA2569079A1 (en) * 2004-06-03 2005-12-15 The Johns Hopkins University Methods of screening for cell proliferation or neoplastic disorders
US7622271B2 (en) 2004-07-26 2009-11-24 University Of Washington Identification of aging genes through large-scale analysis
US20070118398A1 (en) * 2005-11-18 2007-05-24 Flicker Technologies, Llc System and method for estimating life expectancy and providing customized advice for improving life expectancy
JP5292569B2 (ja) * 2006-11-10 2013-09-18 国立大学法人名古屋大学 抗老化転写因子活性化剤及びその利用
KR20160102081A (ko) * 2008-08-10 2016-08-26 쿠아키니 메디컬 센터 건강한 노화 및 장수를 예측하고 증진하기 위하여 ｆｏｘｏ３ａ 다형성 및 일배체형을 사용하는 방법

Also Published As

Publication number Publication date
HK1158271A1 (en) 2012-07-13
CN102177255A (zh) 2011-09-07
US20130295566A1 (en) 2013-11-07
WO2010019519A3 (en) 2010-05-27
US20110212447A1 (en) 2011-09-01
JP2011530312A (ja) 2011-12-22
AU2009282172B2 (en) 2016-06-02
EP2324127A4 (en) 2012-06-13
DK2324127T3 (en) 2015-04-27
US20150337383A1 (en) 2015-11-26
AU2009282172A1 (en) 2010-02-18
KR20160102081A (ko) 2016-08-26
CA2733597A1 (en) 2010-02-18
EP2324127A2 (en) 2011-05-25
KR101649541B1 (ko) 2016-08-19
JP5814119B2 (ja) 2015-11-17
EP2324127B1 (en) 2015-01-21
WO2010019519A2 (en) 2010-02-18
US12534761B2 (en) 2026-01-27
KR20110057147A (ko) 2011-05-31
CN102177255B (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
US12534761B2 (en) Method of using FOXO3A polymorphisms and haplotypes to predict and promote healthy aging and longevity
JP6263499B2 (ja) 変形性関節症に関連する状態に対する遺伝的素因の検出
WO2013043554A1 (en) Methods for creating recommended dietary regime
Tsai et al. Sequence variants of ADIPOQ and association with type 2 diabetes mellitus in Taiwan Chinese Han population
US20100129798A1 (en) Detecting genetic predisposition to osteoarthritis associated conditions
Lorenz et al. Candidate gene analysis of the succinic semialdehyde dehydrogenase gene (ALDH5A1) in patients with idiopathic generalized epilepsy and photosensitivity
TWI351436B (en) Method for detecting a risk of the development of
HK1158271B (en) Method of using foxo3a polymorphisms and haplotypes to predict and promote healthy aging and longevity
US10731219B1 (en) Method for preventing progression to metabolic syndrome
US8236497B2 (en) Methods of diagnosing cardiovascular disease
Sidiropoulou et al. Impact of vitamin D receptor gene variants on psoriasis vulgaris susceptibility and clinical phenotype in a Greek population
Khodyrev et al. The analysis of association between type 2 diabetes and polymorphic markers in the CDKAL1 gene and in the HHEX/IDE locus
US20100184839A1 (en) Allelic polymorphism associated with diabetes
Hansen et al. The Rhesus Monkey: A Nonhuman Primate Model For T2DM-Associated Gene Screening. J Diabetes Metab 2: 150. doi: 10.4172/2155-6156.1000150 Page 2 of 7 Volume 2• Issue 7• 1000150 J Diabetes Metab ISSN: 2155-6156 JDM, an open access journal nucleotide and amino acid levels; c) 89 percent of the rhesus monkey genes are syngenically aligned with the corresponding human genes; and d) an extraordinary amount of physiological similarity exists between rhesus monkeys and humans [13]
WO2006125513A1 (en) Genetic association of polymorphisms in the atf6-alpha gene with insulin resistance phenotypes
WO2011004345A1 (en) Upstream binding protein 1 polymorphisms and their use for prognosing or diagnosing arterial blood pressure

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140807

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240812

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240812

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250808

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250808